Literature DB >> 17260005

Prominent contribution of portal mesenchymal cells to liver fibrosis in ischemic and obstructive cholestatic injuries.

Marc Beaussier1, Dominique Wendum, Eduardo Schiffer, Sylvie Dumont, Colette Rey, André Lienhart, Chantal Housset.   

Abstract

Liver fibrosis is produced by myofibroblasts of different origins. In culture models, rat myofibroblasts derived from hepatic stellate cells (HSCs) and from periductal portal mesenchymal cells, show distinct proliferative and immunophenotypic evolutive profiles, in particular regarding desmin microfilament (overexpressed vs shut-down, respectively). Here, we examined the contributions of both cell types, in two rat models of cholestatic injury, arterial liver ischemia and bile duct ligation (BDL). Serum and (immuno)histochemical hepatic analyses were performed at different time points (2 days, 1, 2 and 6 weeks) after injury induction. Cholestatic liver injury, as attested by serum biochemical tests, was moderate/resolutive in ischemia vs severe and sustained in BDL. Spatio-temporal and morphometric analyses of cytokeratin-19 and Sirius red stainings showed that in both models, fibrosis accumulated around reactive bile ductules, with a significant correlation between the progression rates of fibrosis and of the ductular reaction (both higher in BDL). After 6 weeks, fibrosis was stabilized and did not exceed F2 (METAVIR) in arterial ischemia, whereas micronodular cirrhosis (F4) was established in BDL. Immuno-analyses of alpha-smooth muscle actin and desmin expression profiles showed that intralobular HSCs underwent early phenotypic changes marked by desmin overexpression in both models and that the accumulation of fibrosis coincided with that of alpha-SMA-labeled myofibroblasts around portal/septal ductular structures. With the exception of desmin-positive myofibroblasts located at the portal/septal-lobular interface at early stages, and of myofibroblastic HSCs detected together with fine lobular septa in BDL cirrhotic liver, the vast majority of myofibroblasts were desmin-negative. These findings suggest that both in resolutive and sustained cholestatic injury, fibrosis is produced by myofibroblasts that derive predominantly from portal/periportal mesenchymal cells. While HSCs massively undergo phenotypic changes marked by desmin overexpression, a minority fully converts into matrix-producing myofibroblasts, at sites, which however may be important in the healing process that circumscribes wounded hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17260005     DOI: 10.1038/labinvest.3700513

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  48 in total

Review 1.  Targeting collagen expression in alcoholic liver disease.

Authors:  Kyle J Thompson; Iain H McKillop; Laura W Schrum
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  Overexpression of mcl-1 attenuates liver injury and fibrosis in the bile duct-ligated mouse.

Authors:  Alisan Kahraman; Justin L Mott; Steven F Bronk; Nathan W Werneburg; Fernando J Barreyro; Maria E Guicciardi; Yuko Akazawa; Karen Braley; Ruth W Craig; Gregory J Gores
Journal:  Dig Dis Sci       Date:  2008-12-03       Impact factor: 3.199

Review 3.  Mechanisms of hepatic fibrogenesis.

Authors:  Scott L Friedman
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

4.  Ezrin-radixin-moesin-binding phosphoprotein (EBP50), an estrogen-inducible scaffold protein, contributes to biliary epithelial cell proliferation.

Authors:  Laura Fouassier; Peter Rosenberg; Martine Mergey; Bruno Saubaméa; Audrey Clapéron; Nils Kinnman; Nicolas Chignard; Gunilla Jacobsson-Ekman; Birgitta Strandvik; Colette Rey; Véronique Barbu; Rolf Hultcrantz; Chantal Housset
Journal:  Am J Pathol       Date:  2009-03       Impact factor: 4.307

Review 5.  Extracellular matrix and liver disease.

Authors:  Elena Arriazu; Marina Ruiz de Galarreta; Francisco Javier Cubero; Marta Varela-Rey; María Pilar Pérez de Obanos; Tung Ming Leung; Aritz Lopategi; Aitor Benedicto; Ioana Abraham-Enachescu; Natalia Nieto
Journal:  Antioxid Redox Signal       Date:  2014-01-08       Impact factor: 8.401

Review 6.  The portal fibroblast: not just a poor man's stellate cell.

Authors:  Rebecca G Wells
Journal:  Gastroenterology       Date:  2014-05-09       Impact factor: 22.682

7.  Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice.

Authors:  Kojiro Taura; Kouichi Miura; Keiko Iwaisako; Christoph H Osterreicher; Yuzo Kodama; Melitta Penz-Osterreicher; David A Brenner
Journal:  Hepatology       Date:  2010-03       Impact factor: 17.425

Review 8.  Cellular sources of extracellular matrix in hepatic fibrosis.

Authors:  Rebecca G Wells
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

9.  Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy.

Authors:  Angela Douglass; Karen Wallace; Matthew Koruth; Caroline Barelle; Andrew J Porter; Matthew C Wright
Journal:  Hepatol Int       Date:  2008-09-03       Impact factor: 6.047

10.  Development and evaluation of an open source Delphi-based software for morphometric quantification of liver fibrosis.

Authors:  Sebastian Huss; Jörg Schmitz; Diane Goltz; Hans-Peter Fischer; Reinhard Büttner; Ralf Weiskirchen
Journal:  Fibrogenesis Tissue Repair       Date:  2010-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.